Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 176 | 44% |
| 2020 | 5 | 148 | 46% |
| 2021 | 6 | 247 | 49% |
| 2022 | 6 | 201 | 51% |
| 2023 | 7 | 282 | 53% |
| 2024 | 12 | 342 | 54% |
| 2025 from claims | – | 481 389–565 | 55% |
| 2026 forecast | – | 530 415–665 | 55% |
| 2027 forecast | – | 581 431–769 | 56% |
| 2028 forecast | – | 638 452–881 | 56% |
| 2029 forecast | – | 700 476–1,004 | 57% |
| 2030 forecast | – | 768 503–1,140 | 57% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 90% of the cases CMS names in Arizona; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| Forecast, Medicare FFS | Inpatient |
|---|---|
| 2026 · ~530 | ~530 |
| 2027 · ~580 | ~580 |
| 2028 · ~640 | ~640 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 48 | 1,774+17%/yr | +17%/yr | 0.5 | 0% | 3,530 in 2030+12%/yr |
| Washington | 12 | 398+16%/yr | +16%/yr | 0.5 | 0% | 840 in 2030+13%/yr |
| Colorado | 6 | 214+15%/yr | +15%/yr | 0.4 | 0% | 430 in 2030+12%/yr |
| Nevada | 3 | 177+15%/yr | +15%/yr | 0.6 | 0% | 310 in 2030+9.8%/yr |
| Oregon | 2 | 108+11%/yr | +11%/yr | 0.3 | 0% | 150 in 2030+5.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| DBS & VNS | 4 | 305−10%/yr | −10%/yr | 0.41.3× | 0% | 540 in 2030+9.8%/yr |
| Stroke thrombectomy | 10 | 233+2.7%/yr | +2.7%/yr | 0.30.8× | 0% | 280 in 2030+3%/yr |
| CSF shunts | 3 | 152−8%/yr | −8%/yr | 0.21.0× | 0% | 170 in 2030+1.6%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Stryker leads with 26% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 9 companies reported engagement with Arizona’s surgeons worth $66K in consulting, speaking, meals and travel tied to these products, about $5,459 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.